{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:03:10Z","timestamp":1790650990466,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R01 ES017537"],"award-info":[{"award-number":["R01 ES017537"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.taap.2017.05.018","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T19:16:20Z","timestamp":1495048580000},"page":"54-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Von Willebrand factor deficiency reduces liver fibrosis in mice"],"prefix":"10.1016","volume":"328","author":[{"given":"Nikita","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Kopec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Cline-Fedewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna J.","family":"Groeneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton","family":"Lisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Luyendyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2017.05.018_bb0005","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1538-7836.2008.03015.x","article-title":"Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies","volume":"6","author":"Anstee","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.taap.2017.05.018_bb0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.clinre.2011.03.011","article-title":"The role of hypercoagulability in liver fibrogenesis","volume":"35","author":"Anstee","year":"2011","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.taap.2017.05.018_bb0015","first-page":"524","article-title":"Strain differences in mice in carbon tetrachloride-induced liver injury","volume":"64","author":"Bhathal","year":"1983","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.taap.2017.05.018_bb0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/STROKEAHA.111.628867","article-title":"Von Willebrand factor: an emerging target in stroke therapy","volume":"43","author":"De Meyer","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.taap.2017.05.018_bb0025","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1073\/pnas.95.16.9524","article-title":"A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis","volume":"95","author":"Denis","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2017.05.018_bb0030","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/hep.25806","article-title":"Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis","volume":"56","author":"Ferlitsch","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2017.05.018_bb0035","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hep.510230613","article-title":"High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia","volume":"23","author":"Ferro","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2017.05.018_bb0040","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/gut.2007.144550","article-title":"Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease","volume":"57","author":"Fujita","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.taap.2017.05.018_bb0045","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.21779","article-title":"Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice","volume":"46","author":"Ganey","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.taap.2017.05.018_bb0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/bjs.10107","article-title":"Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy","volume":"103","author":"Groeneveld","year":"2016","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.taap.2017.05.018_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1160\/TH03-05-0310","article-title":"Factor VIII expression in liver disease","volume":"91","author":"Hollestelle","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.taap.2017.05.018_bb0060","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/hep.26372","article-title":"An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome","volume":"58","author":"Hugenholtz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2017.05.018_bb0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/gutjnl-2012-303088","article-title":"Anticoagulation in patients with liver cirrhosis: complication or therapeutic opportunity?","volume":"62","author":"Jairath","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.taap.2017.05.018_bb0070","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/blood-2015-09-670703","article-title":"Fibrin deposition following bile duct injury limits fibrosis through an alphaMbeta2-dependent mechanism","volume":"127","author":"Joshi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.taap.2017.05.018_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1679\/aohc1950.41.267","article-title":"Differential staining of collagens type I, II and III by Sirius Red and polarization microscopy","volume":"41","author":"Junqueira","year":"1978","journal-title":"Archivum Histologicum Japonicum=Nihon Soshikigaku Kiroku"},{"key":"10.1016\/j.taap.2017.05.018_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bjp.0701354","article-title":"Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor","volume":"122","author":"Kageyama","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2017.05.018_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/hq0102.101520","article-title":"Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys","volume":"22","author":"Kageyama","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.taap.2017.05.018_bb0090","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jhep.2016.06.002","article-title":"Von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia","volume":"65","author":"Kalambokis","year":"2016","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.taap.2017.05.018_bb0095","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2016.12.004","article-title":"Fibri(nogen) drives repair after acetaminophen-induced liver injury via leukocyte alphaMbeta2 integrin-dependent upregulation of MMP12","volume":"66","author":"Kopec","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.05.018_bb0100","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/gut.2010.235689","article-title":"Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension","volume":"60","author":"La Mura","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.taap.2017.05.018_bb0105","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2017.05.018_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.21231","article-title":"Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity","volume":"44","author":"Lisman","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2017.05.018_bb0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2010.01.042","article-title":"Hemostasis and thrombosis in patients with liver disease: the ups and downs","volume":"53","author":"Lisman","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.05.018_bb0120","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhep.2013.03.027","article-title":"Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats","volume":"59","author":"Lisman","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.05.018_bb0125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/apt.12564","article-title":"Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"39","author":"Maieron","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2017.05.018_bb0130","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.jhep.2015.07.026","article-title":"Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population: the Rotterdam Study","volume":"63","author":"Plompen","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.05.018_bb0135","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clinre.2014.07.004","article-title":"Aspirin may reduce liver fibrosis progression: evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation","volume":"38","author":"Poujol-Robert","year":"2014","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.taap.2017.05.018_bb0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/liv.12657","article-title":"Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis","volume":"35","author":"Reuken","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.taap.2017.05.018_bb0145","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1538-7836.2003.00260.x","article-title":"Von Willebrand factor, platelets and endothelial cell interactions","volume":"1","author":"Ruggeri","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.taap.2017.05.018_bb0150","doi-asserted-by":"crossref","first-page":"G226","DOI":"10.1152\/ajpgi.00444.2007","article-title":"Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis","volume":"294","author":"Rullier","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.taap.2017.05.018_bb0155","first-page":"2","article-title":"Automated quantification of renal fibrosis with Sirius Red and polarization contrast microscopy","author":"Street","year":"2014","journal-title":"Phys. Rep."},{"key":"10.1016\/j.taap.2017.05.018_bb0160","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.2353\/ajpath.2010.100425","article-title":"The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis","volume":"177","author":"Sullivan","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.taap.2017.05.018_bb0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/MOH.0000000000000164","article-title":"Hemostasis abnormalities in cirrhosis","volume":"22","author":"Tripodi","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.taap.2017.05.018_bb0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2017.05.018_bb0175","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/j.1538-7836.2011.04429.x","article-title":"Hypercoagulability in cirrhosis: causes and consequences","volume":"9","author":"Tripodi","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.taap.2017.05.018_bb0180","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"issue":"1253\u20131260","key":"10.1016\/j.taap.2017.05.018_bb0185","first-page":"e1251","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17302120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17302120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T19:45:24Z","timestamp":1569354324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X17302120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":37,"alternative-id":["S0041008X17302120"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2017.05.018","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Von Willebrand factor deficiency reduces liver fibrosis in mice","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2017.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}